Skip to content

Uridine monophosphate and mood: grade D

Preliminary evidence. Direction: Benefit.

Evidence maturity: Mechanistic onlyShort-term onlySingle research group

Why this grade

Rubric condition met: D: no controlled human outcome data; an uncontrolled case series counts as D. The only human mood data is one 6-week open-label case series, n = 7, in adolescents with bipolar disorder (a clinical population)

The only human mood data found is an uncontrolled case series of seven adolescents with bipolar disorder in which uridine was associated with lower symptom scores. With no placebo group, expectation and natural fluctuation cannot be excluded, and the population is clinical. A 7-day placebo-controlled brain spectroscopy study in 17 healthy men from an overlapping research group measured phospholipid precursors, not mood. With no controlled outcome data, the grade is D.

How sure are we?

Evidence maturity: Mechanistic only The only human mood data is an uncontrolled, open-label case series of 7 adolescents; the human data are uncontrolled, which the method files under Mechanistic only.

Tested as: Uridine or uridine monophosphate

Who paid for the studies
Not stated (treated as not independent)
Risk of bias
High. Uncontrolled case series.
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Doses used in studies
Grams a day
Rules applied
Uncontrolled data only (logged, no further change): Uncontrolled case series of 7
  • Could rise: Would move to C with any controlled trial, or an open-label trial with a prespecified outcome; to B only with two RCTs in a defined population.
  • Could fall: Would move to N only with adequately sized controlled trials that find no effect.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.

Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
Traditional use only
a traditional-use monograph and nothing else

How we grade evidence

Studies this grade rests on

EffectMixedNo effectSize shows participants (n)201020152020RCTOpen-label studyAgarwal 2010, 2010: RCT, n = 17, result not recordedKondo 2011, 2011: open-label study, n = 7, result not recorded
each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.
Show the numbers
StudyYearDesignParticipantsResult
Agarwal 20102010RCT17result not recorded
Kondo 20112011open-label study7result not recorded

Open-label uridine for treatment of depressed adolescents with bipolar disorder.

Kondo DG, Sung YH, Hellem TL. Open-label uridine for treatment of depressed adolescents with bipolar disorder J Child Adolesc Psychopharmacol, 2011. PMID 21486171

Result not recorded
Design
Open-label case series (6 weeks), no control group
Sample
n = 7
Population
Adolescents with bipolar disorder in a depressive episode (clinical population)
Funding
NIDA NIH HHS K05 DA031247, NIMH NIH HHS R01 MH058681, NIMH NIH HHS R33 MH096858

Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T.

Agarwal N, Sung YH, Jensen JE. Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T Bipolar Disord, 2010. PMID 21176029

Result not recorded
Design
Randomized, placebo-controlled study (7 days), brain 31P-MRS outcome
Sample
n = 17
Population
Healthy adult men
Funding
NIDA NIH HHS K05 DA031247, NIMH NIH HHS MH58681, NIMH NIH HHS R01 MH058681

Search and history

Search (): uridine[ti] AND (mood[tiab] OR depress*[tiab] OR bipolar[tiab]) AND humans[mh]

  • Graded C (awaiting approval)
  • C to D (awaiting approval): Modifiers kept because the single 6-week series is short-term and from one group.
  • D to D (awaiting approval) (maturity: mechanistic only): Maturity, bias summary and re-check date added
  • D to D (approved) (maturity: mechanistic only): Editor sign-off November 16, 2026: grade matches the editor-approved final page